Ampio pharmaceuticals announces patient randomization and dosing in ap-019 phase ii study of inhaled ampion in covid-19 respiratory distress

Englewood, colo., june 25, 2021 /prnewswire/ --  ampio pharmaceuticals  (nyse american: ampe), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced randomization and dosing of patients in its multi-center ap-019 phase ii clinical trial, using inhaled ampion™ in the treatment of respiratory distress due to covid-19, is underway.
AMPE Ratings Summary
AMPE Quant Ranking